Eisai Co., Ltd. Logo

Eisai Co., Ltd.

ESAIY

()
Stock Price

7,50 USD

2.99% ROA

3.79% ROE

7324.49x PER

Market Cap.

1.587.504.141.785,60 USD

20.36% DER

0% Yield

4.42% NPM

Eisai Co., Ltd. Stock Analysis

Eisai Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Eisai Co., Ltd. Fundamental Stock Analysis
# Analysis Rating

Eisai Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Eisai Co., Ltd. Technical Stock Analysis
# Analysis Recommendation

Eisai Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Eisai Co., Ltd. Revenue
Year Revenue Growth
2016 4.978.385.796
2017 5.414.065.576 8.05%
2018 5.796.797.960 6.6%
2019 6.397.940.303 9.4%
2020 6.090.493.101 -5.05%
2021 6.729.625.444 9.5%
2022 5.493.033.836 -22.51%
2023 5.129.593.208 -7.09%
2024 4.852.242.556 -5.72%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Eisai Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2016 962.927.306
2017 1.182.767.621 18.59%
2018 1.150.866.848 -2.77%
2019 1.154.188.169 0.29%
2020 1.308.932.432 11.82%
2021 1.406.302.757 6.92%
2022 1.156.242.144 -21.63%
2023 1.058.710.650 -9.21%
2024 1.071.334.004 1.18%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Eisai Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 281.630.000.000 100%
2021 366.430.000.000 23.14%
2022 358.292.000.000 -2.27%
2023 374.421.000.000 4.31%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Eisai Co., Ltd. EBITDA
Year EBITDA Growth
2016 717.432.690
2017 918.305.300 21.87%
2018 1.143.084.690 19.66%
2019 1.585.447.470 27.9%
2020 875.393.710 -81.11%
2021 872.285.020 -0.36%
2022 584.433.910 -49.25%
2023 595.771.970 1.9%
2024 463.433.600 -28.56%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Eisai Co., Ltd. Gross Profit
Year Gross Profit Growth
2016 3.057.517.908
2017 3.488.139.964 12.35%
2018 4.025.766.052 13.35%
2019 4.693.937.690 14.23%
2020 4.386.171.086 -7.02%
2021 5.070.547.709 13.5%
2022 4.010.368.812 -26.44%
2023 3.898.789.866 -2.86%
2024 3.831.708.104 -1.75%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Eisai Co., Ltd. Net Profit
Year Net Profit Growth
2016 363.467.588
2017 467.778.282 22.3%
2018 571.587.432 18.16%
2019 1.119.946.058 48.96%
2020 397.133.920 -182.01%
2021 426.740.760 6.94%
2022 409.039.539 -4.33%
2023 293.266.418 -39.48%
2024 271.606.888 -7.97%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Eisai Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 0
2017 0 0%
2018 1 0%
2019 1 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Eisai Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2016 515.756.620
2017 1.127.070.923 54.24%
2018 686.164.625 -64.26%
2019 483.381.253 -41.95%
2020 336.694.963 -43.57%
2021 686.314.545 50.94%
2022 -268.090.912 356%
2023 215.556.730 224.37%
2024 -91.215.865 336.31%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Eisai Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2016 700.459.362
2017 1.350.227.645 48.12%
2018 935.247.830 -44.37%
2019 945.332.444 1.07%
2020 696.349.187 -35.76%
2021 1.046.428.787 33.45%
2022 -13.075.805 8102.79%
2023 387.220.660 103.38%
2024 -55.067.070 803.18%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Eisai Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2016 184.702.742
2017 223.156.722 17.23%
2018 249.083.205 10.41%
2019 461.951.191 46.08%
2020 359.654.224 -28.44%
2021 360.114.242 0.13%
2022 255.015.107 -41.21%
2023 171.663.930 -48.55%
2024 36.148.795 -374.88%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Eisai Co., Ltd. Equity
Year Equity Growth
2016 5.407.798.617
2017 5.774.311.236 6.35%
2018 5.890.427.789 1.97%
2019 6.508.545.226 9.5%
2020 6.587.710.406 1.2%
2021 6.356.605.561 -3.64%
2022 6.180.562.025 -2.85%
2023 5.939.905.513 -4.05%
2024 5.717.369.140 -3.89%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Eisai Co., Ltd. Assets
Year Assets Growth
2016 9.250.327.559
2017 9.863.949.224 6.22%
2018 9.680.805.890 -1.89%
2019 9.838.729.100 1.61%
2020 9.864.334.841 0.26%
2021 10.210.628.218 3.39%
2022 9.492.448.718 -7.57%
2023 9.209.415.573 -3.07%
2024 8.829.087.405 -4.31%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Eisai Co., Ltd. Liabilities
Year Liabilities Growth
2016 3.842.519.967
2017 4.089.647.390 6.04%
2018 3.790.387.134 -7.9%
2019 3.330.174.609 -13.82%
2020 3.276.624.434 -1.63%
2021 3.854.014.418 14.98%
2022 3.311.886.693 -16.37%
2023 3.269.516.667 -1.3%
2024 3.111.718.264 -5.07%

Eisai Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
4.29
Net Income per Share
0.19
Price to Earning Ratio
7324.49x
Price To Sales Ratio
322.71x
POCF Ratio
6636.9
PFCF Ratio
9509.65
Price to Book Ratio
285.67
EV to Sales
322.55
EV Over EBITDA
3651.83
EV to Operating CashFlow
6619.97
EV to FreeCashFlow
9505.13
Earnings Yield
0
FreeCashFlow Yield
0
Market Cap
1.587,50 Bil.
Enterprise Value
1.586,75 Bil.
Graham Number
4.55
Graham NetNet
0.29

Income Statement Metrics

Net Income per Share
0.19
Income Quality
1.1
ROE
0.04
Return On Assets
0.02
Return On Capital Employed
0.02
Net Income per EBT
0.66
EBT Per Ebit
1.96
Ebit per Revenue
0.03
Effective Tax Rate
0.31

Margins

Sales, General, & Administrative to Revenue
58.61
Research & Developement to Revenue
0.23
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.79
Operating Profit Margin
0.03
Pretax Profit Margin
0.07
Net Profit Margin
0.04

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
1.42
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.21
Free CashFlow per Share
0.15
Capex to Operating CashFlow
0.3
Capex to Revenue
0.01
Capex to Depreciation
0.27
Return on Invested Capital
0.02
Return on Tangible Assets
0.03
Days Sales Outstanding
94.72
Days Payables Outstanding
174.23
Days of Inventory on Hand
426.86
Receivables Turnover
3.85
Payables Turnover
2.09
Inventory Turnover
0.86
Capex per Share
0.06

Balance Sheet

Cash per Share
1,65
Book Value per Share
4,99
Tangible Book Value per Share
3.63
Shareholders Equity per Share
4.86
Interest Debt per Share
2.62
Debt to Equity
0.2
Debt to Assets
0.13
Net Debt to EBITDA
-1.74
Current Ratio
2.36
Tangible Asset Value
4,16 Bil.
Net Current Asset Value
1,45 Bil.
Invested Capital
5214926021
Working Capital
2,62 Bil.
Intangibles to Total Assets
0.18
Average Receivables
1,35 Bil.
Average Payables
0,32 Bil.
Average Inventory
1169440006
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Eisai Co., Ltd. Dividends
Year Dividends Growth

Eisai Co., Ltd. Profile

About Eisai Co., Ltd.

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

CEO
Mr. Haruo Naito
Employee
11.067
Address
4-6-10, Koishikawa
Tokyo, 112-8088

Eisai Co., Ltd. Executives & BODs

Eisai Co., Ltd. Executives & BODs
# Name Age
1 Shin Kato
Vice President, General Counsel & Chief Compliance Officer
70
2 Ms. Yanhui Feng
Senior Vice President
70
3 Mr. Keisuke Naito
Representative Corporate Officer, EVice President, Chief Operating Officer & Chief Growth Officer
70
4 Dr. Lynn D. Kramer FAAN, M.D.
Vice President & Chief Clinical Officer
70
5 Mr. Haruo Naito
Chief Executive Officer, Representative Corporate Officer & Director
70
6 Mitsuru Shomon
Vice President & Chief Financial Officer
70
7 Makoto Hoketsu
Vice President & Chief Information Officer
70
8 Mr. Masatomi Akana
Senior Vice President, Chief Government Relations Officer & Chief IR Officer
70
9 Ms. Sayoko Sasaki
Vice President of Corporate Communications & Sustainability
70
10 Mr. Gary Hendler
Senior Vice President & President of EMEA Region
70

Eisai Co., Ltd. Competitors